© Reuters. Spineway: down on the degradation of analyst
Spineway fall of 3% on the background of the degradation of recommendation at Invest Securities ‘buy’ to ‘neutral’ with a price target lowered from 5.2 to 4.8 euros, after what he considered to be a ‘good vintage’ in 2017.
‘While the year 2017 has been marked by a significant sales growth (+77%), the future looks more challenging for the company’, says the analyst, noting that this hyper growth ‘should be at the price of a strong increase in OPEX’.
The office of education revises its estimates of operational expenditure (OPEX) for the medical technology company in the medium term and offsets and the achievement of profitability in 2019 (versus 2018 previously).
Copyright (c) 2018 CercleFinance.com. All rights reserved.